source
- GSK to acquire Nuvalent for $11 billion, adding two lung-cancer drugs under FDA reviewGSK announced a deal to buy Massachusetts‑based biotech Nuvalent for $11 billion. The acquisition brings two experimental lung‑cancer medicines that are currently under review by the U.S. Food and…
- U.S. drug shortages drop 23% but average duration climbs to over five years, analysis showsThe latest U.S. Pharmacopeia analysis reports that the total number of prescription drug shortages fell by 23% last year, marking the second year of decline and the lowest level since 2017. Despit…